JAK2 and antiphospholipid syndrome: We were not able to collect data on potential predictors of breakthrough PE beyond active cancer diagnosis as testing for antiphospholipid syndrome, established myeloproliferative neoplasm, and JAK2 V617F mutation are not routine in our system.